Savara (NASDAQ:SVRA) Shares Up 7.3% – Still a Buy?

Shares of Savara Inc. (NASDAQ:SVRA) were up 7.3% during trading on Wednesday . The stock traded as high as $4.44 and last traded at $4.4730. Approximately 992,334 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 1,324,706 shares. The stock had previously closed at $4.17.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Wells Fargo & Company initiated coverage on shares of Savara in a research note on Monday, October 20th. They set an “overweight” rating and a $7.00 price target on the stock. Guggenheim raised their price objective on shares of Savara from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, September 9th. Citigroup reissued an “outperform” rating on shares of Savara in a research note on Thursday, October 23rd. Oppenheimer increased their price target on shares of Savara from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Friday, November 14th. Finally, Citizens Jmp decreased their price objective on Savara from $11.00 to $10.00 and set a “market outperform” rating on the stock in a report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.29.

Savara Stock Up 12.1%

The firm has a market capitalization of $951.21 million, a price-to-earnings ratio of -9.27 and a beta of 0.45. The firm has a fifty day moving average price of $3.82 and a 200 day moving average price of $3.07. The company has a current ratio of 11.08, a quick ratio of 11.08 and a debt-to-equity ratio of 0.25.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Sell-side analysts anticipate that Savara Inc. will post -0.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Savara

A number of hedge funds have recently added to or reduced their stakes in the stock. VR Adviser LLC lifted its holdings in Savara by 172.7% during the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after buying an additional 5,626,624 shares in the last quarter. Bain Capital Life Sciences Investors LLC raised its position in shares of Savara by 20.8% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company’s stock worth $48,754,000 after acquiring an additional 3,035,164 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in shares of Savara by 32.4% during the first quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company’s stock worth $31,751,000 after acquiring an additional 2,801,922 shares during the last quarter. Rosalind Advisors Inc. lifted its stake in shares of Savara by 50.7% during the third quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock valued at $14,280,000 after acquiring an additional 1,345,056 shares during the period. Finally, Millennium Management LLC bought a new position in Savara in the third quarter valued at about $3,014,000. Institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.